Bioqual, Inc.

Bioqual, Inc. is a for-profit biomedical research services company located in Rockville, Maryland, specializing in providing advanced scientific research support to federal agencies. Registered in the System for Award Management (SAM) since 1999, the company offers comprehensive services in animal research, laboratory analysis, and experimental studies across multiple scientific domains. Bioqual primarily serves federal research institutions, with a strong focus on conducting preclinical studies for agencies like the National Institutes of Health (NIH), particularly the National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.

Through federal contract awards, Bioqual has consistently provided sophisticated research services involving animal studies and laboratory analysis. Their contract work spans multiple scientific domains, including infectious disease research, vaccine development, and therapeutic studies. The company has received contracts involving humanized mice studies, SARS-COV-2 hamster research, and non-human primate models for various scientific investigations. Most of their federal contract awards have been firm fixed-price or cost-plus-fixed-fee purchase orders and delivery orders, primarily from NIH institutes. These contracts typically involve conducting specialized research studies, providing laboratory analysis, and supporting animal housing and care. Notably, none of their recent contract awards have been set aside for specific business types, indicating Bioqual competes in open federal procurement processes.

Regarding federal grant awards, Bioqual has been involved in sub-grant work supporting cutting-edge medical research, particularly in HIV cure research and vaccine development. Their grant-related activities have involved collaborating with prominent research institutions like Temple University, University of Maryland, and University of Pennsylvania. These sub-grant projects have focused on innovative research areas such as developing multiomic signatures for vaccine mechanism evaluation, exploring CRISPR technologies for HIV cure strategies, and conducting advanced immunological and virological studies. The grant work demonstrates Bioqual's expertise in supporting complex, interdisciplinary research projects that aim to advance medical understanding and potential therapeutic interventions.

Bioqual holds two significant indefinite delivery contracts (IDVs) that underscore its strategic importance in federal research infrastructure. The first is a $146.3 million single-award IDC with NIAID, running until July 2031, focused on developing and refining animal models for evaluating countermeasures against infectious diseases. This contract covers four primary task areas: small animal models, non-human primate models, animal replacement models, and specialized reagent generation. The second is a $545 million multiple-award IDIQ contract with NIAID's Comprehensive and Rapid Response Research Programs, operating from September 2021 to August 2028. This contract supports a broad range of research services including clinical trials, manufacturing, nonclinical animal studies, analytics, storage, and regulatory support across the agency's research divisions.